Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by SkyOak Wealth LLC

SkyOak Wealth LLC trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.2% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,065 shares of the medical equipment provider’s stock after selling 890 shares during the period. SkyOak Wealth LLC’s holdings in Lantheus were worth $3,217,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Farallon Capital Management LLC grew its holdings in shares of Lantheus by 595.3% in the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock valued at $92,316,000 after purchasing an additional 1,269,900 shares in the last quarter. Norges Bank purchased a new stake in shares of Lantheus during the fourth quarter worth $29,956,000. Swedbank AB acquired a new stake in shares of Lantheus in the first quarter valued at $26,346,000. Nomura Holdings Inc. boosted its holdings in Lantheus by 105.3% in the fourth quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider’s stock valued at $1,282,000 after purchasing an additional 407,507 shares during the period. Finally, Westfield Capital Management Co. LP grew its stake in Lantheus by 25.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after purchasing an additional 394,837 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Lantheus

In related news, Director Gary J. Pruden sold 12,530 shares of the company’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the transaction, the director now owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gary J. Pruden sold 12,530 shares of the business’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the sale, the director now owns 11,978 shares in the company, valued at $1,138,389.12. The disclosure for this sale can be found here. In the last three months, insiders sold 40,852 shares of company stock valued at $3,922,001. Corporate insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $105.54 on Wednesday. The stock has a fifty day moving average price of $106.04 and a 200 day moving average price of $83.44. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The company has a market cap of $7.32 billion, a PE ratio of 16.11 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm’s revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the business posted $1.40 EPS. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on LNTH shares. B. Riley lifted their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. JMP Securities decreased their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Leerink Partners increased their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, July 11th. Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. Finally, Truist Financial dropped their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.